{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:46:49Z","timestamp":1787611609681,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) still experience a high rate of in-hospital complications. Liver fibrosis (LF) is a risk factor for mortality in the general population. We investigated whether the presence of LF detected by the validated fibrosis 4 (FIB-4) score may indicate ACS patients at higher risk of poor outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the prospective ongoing REAl-world observationaL rEgistry of Acute Coronary Syndrome (REALE-ACS), LF was defined by a FIB-4 score\u2009&gt;\u20093.25. We repeated the analysis using an APRI score\u2009&gt;\u20090.7. The primary endpoint was in-hospital adverse events (AEs) including a composite of in-hospital cardiogenic shock, PEA\/asystole, acute pulmonary edema and death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 469 consecutive ACS consecutive patients were enrolled. Overall, 21.1% of patients had a FIB-4 score\u2009&gt;\u20093.25. Patients with LF were older, less frequently on P2Y12 inhibitors (<jats:italic>p<\/jats:italic>\u2009=\u20090.021) and admitted with higher serum levels of white blood cells (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), neutrophils to lymphocytes ratio (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), C-reactive protein (<jats:italic>p<\/jats:italic>\u2009=\u20090.013), hs-TnT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), creatine-kinase MB (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), D-Dimer levels (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). STEMI presentation and higher Killip class\/GRACE score were more common in the LF group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). 71 patients experienced 110 AEs. At the multivariate analysis including clinical and laboratory risk factors, FIB-4\u2009&gt;\u20093.25 (OR 3.1, 95%CI 1.4\u20136.9), admission left ventricular ejection fraction% below median (OR 9.2, 95%CI 3.9\u201321.7) and Killip class\u2009\u2265\u2009II (OR 6.3, 95%CI 2.2\u201318.4) were the strongest independent predictors of in-hospital AEs. Similar results were obtained using the APRI score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>LF detected by FIB-4 score\u2009&gt;\u20093.25 was associated with more severe ACS presentation and worse in-hospital AEs irrespective of clinical and laboratory variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-022-02078-z","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T06:04:52Z","timestamp":1660197892000},"page":"236-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI"],"prefix":"10.1007","volume":"112","author":[{"given":"Flavio Giuseppe","family":"Biccir\u00e8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barill\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Sammartini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Maria","family":"Dacierno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Tanzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"issue":"42","key":"2078_CR1","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","volume":"37","author":"N Townsend","year":"2016","unstructured":"Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M (2016) Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 37(42):3232\u20133245. https:\/\/doi.org\/10.1093\/eurheartj\/ehw334","journal-title":"Eur Heart J"},{"issue":"19","key":"2078_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M (2015) Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 36(19):1163\u20131170. https:\/\/doi.org\/10.1093\/eurheartj\/ehu505","journal-title":"Eur Heart J"},{"issue":"17","key":"2078_CR3","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1161\/circulationaha.114.008720","volume":"132","author":"GA Roth","year":"2015","unstructured":"Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M, Murray CJ (2015) Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 132(17):1667\u20131678. https:\/\/doi.org\/10.1161\/circulationaha.114.008720","journal-title":"Circulation"},{"issue":"2","key":"2078_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jacc.2015.05.030","volume":"66","author":"BJ Hirsh","year":"2015","unstructured":"Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS (2015) Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement. J Am Coll Cardiol 66(2):184\u2013192. https:\/\/doi.org\/10.1016\/j.jacc.2015.05.030","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2078_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195174","volume":"13","author":"S Canivell","year":"2018","unstructured":"Canivell S, Muller O, Gencer B, Heg D, Klingenberg R, R\u00e4ber L, Carballo D, Matter C, L\u00fcscher T, Windecker S, Mach F, Rodondi N, Nanchen D (2018) Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. PLoS ONE 13(4):e0195174. https:\/\/doi.org\/10.1371\/journal.pone.0195174","journal-title":"PLoS ONE"},{"key":"2078_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa575","author":"JP Collet","year":"2020","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, J\u00fcni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM (2020) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"issue":"6","key":"2078_CR7","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6):2005\u20132023. https:\/\/doi.org\/10.1002\/hep.25762","journal-title":"Hepatology"},{"issue":"5","key":"2078_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.20524\/aog.2019.0406","volume":"32","author":"N Papadopoulos","year":"2019","unstructured":"Papadopoulos N, Vasileiadi S, Papavdi M, Sveroni E, Antonakaki P, Dellaporta E, Koutli E, Michalea S, Manolakopoulos S, Koskinas J, Deutsch M (2019) Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography. Ann Gastroenterol 32(5):498\u2013503. https:\/\/doi.org\/10.20524\/aog.2019.0406","journal-title":"Ann Gastroenterol"},{"key":"2078_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijcard.2018.01.097","volume":"264","author":"D Pastori","year":"2018","unstructured":"Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, Marcucci R, Grifoni E, Pignatelli P, Violi F, group A-As (2018) Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Int J Cardiol 264:58\u201363. https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.097","journal-title":"Int J Cardiol"},{"issue":"1","key":"2078_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/0003319719844933","volume":"71","author":"Y Turan","year":"2020","unstructured":"Turan Y (2020) The nonalcoholic fatty liver disease fibrosis score is related to epicardial fat thickness and complexity of coronary artery disease. Angiology 71(1):77\u201382. https:\/\/doi.org\/10.1177\/0003319719844933","journal-title":"Angiology"},{"key":"2078_CR11","doi-asserted-by":"publisher","first-page":"8825615","DOI":"10.1155\/2020\/8825615","volume":"2020","author":"A Ismaiel","year":"2020","unstructured":"Ismaiel A, Popa SL, Dumitrascu DL (2020) Acute coronary syndromes and nonalcoholic fatty liver disease: \u201cun affaire de coeur.\u201d Can J Gastroenterol Hepatol 2020:8825615. https:\/\/doi.org\/10.1155\/2020\/8825615","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"2","key":"2078_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsk\u00fd P (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119\u2013177. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"issue":"10","key":"2078_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ (2009) Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7(10):1104\u20131112. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2078_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.03.010","volume":"299","author":"Q Chen","year":"2020","unstructured":"Chen Q, Li Q, Li D, Chen X, Liu Z, Hu G, Wang J, Ling W (2020) Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis 299:45\u201352. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.03.010","journal-title":"Atherosclerosis"},{"issue":"10","key":"2078_CR15","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/j.numecd.2021.06.003","volume":"31","author":"FG Biccir\u00e9","year":"2021","unstructured":"Biccir\u00e9 FG, Pastori D, Tanzilli A, Pignatelli P, Viceconte N, Barill\u00e0 F, Versaci F, Gaudio C, Violi F, Tanzilli G (2021) Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. Nutr Metab Cardiovasc Dis 31(10):2904\u20132911. https:\/\/doi.org\/10.1016\/j.numecd.2021.06.003","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2078_CR16","doi-asserted-by":"publisher","first-page":"659446","DOI":"10.3389\/fcvm.2021.659446","volume":"8","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wang S, Fang S, Yu B (2021) Prognostic role of high sensitivity C-reactive protein in patients with acute myocardial infarction. Front Cardiovasc Med 8:659446\u2013659446. https:\/\/doi.org\/10.3389\/fcvm.2021.659446","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2078_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12872-018-0812-6","volume":"18","author":"S Zhang","year":"2018","unstructured":"Zhang S, Diao J, Qi C, Jin J, Li L, Gao X, Gong L, Wu W (2018) Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis. BMC Cardiovasc Disord 18(1):75. https:\/\/doi.org\/10.1186\/s12872-018-0812-6","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2078_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12959-021-00354-y","volume":"19","author":"FG Biccir\u00e8","year":"2021","unstructured":"Biccir\u00e8 FG, Farcomeni A, Gaudio C, Pignatelli P, Tanzilli G, Pastori D (2021) D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis. Thromb J 19(1):102. https:\/\/doi.org\/10.1186\/s12959-021-00354-y","journal-title":"Thromb J"},{"issue":"18","key":"2078_CR19","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1093\/eurheartj\/ehs154","volume":"33","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS (2012) How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 33(18):2252\u20132257. https:\/\/doi.org\/10.1093\/eurheartj\/ehs154","journal-title":"Eur Heart J"},{"issue":"5","key":"2078_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/eci.12065","volume":"43","author":"M Boddi","year":"2013","unstructured":"Boddi M, Tarquini R, Chiostri M, Marra F, Valente S, Giglioli C, Gensini GF, Abbate R (2013) Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. Eur J Clin Invest 43(5):429\u2013438. https:\/\/doi.org\/10.1111\/eci.12065","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"2078_CR21","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/hep4.1254","volume":"2","author":"K Schwarzkopf","year":"2018","unstructured":"Schwarzkopf K, Bojunga J, R\u00fcschenbaum S, Martinez Y, M\u00fccke MM, Seeger F, Schoelzel F, Zeuzem S, Friedrich-Rust M, Lange CM (2018) Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease. Hepatol Commun 2(12):1601\u20131609. https:\/\/doi.org\/10.1002\/hep4.1254","journal-title":"Hepatol Commun"},{"issue":"5","key":"2078_CR22","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/hep.28526","volume":"64","author":"A Chauhan","year":"2016","unstructured":"Chauhan A, Adams DH, Watson SP, Lalor PF (2016) Platelets: No longer bystanders in liver disease. Hepatology 64(5):1774\u20131784. https:\/\/doi.org\/10.1002\/hep.28526","journal-title":"Hepatology"},{"issue":"11","key":"2078_CR23","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/gut.2007.144550","volume":"57","author":"K Fujita","year":"2008","unstructured":"Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Iwasaki T, Inamori M, Abe Y, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nagashima Y, Nakajima A (2008) Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 57(11):1583\u20131591. https:\/\/doi.org\/10.1136\/gut.2007.144550","journal-title":"Gut"},{"key":"2078_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11040689","author":"A Jichitu","year":"2021","unstructured":"Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, Iurciuc S, Rus M, Bacalbasa N, Diaconu CC (2021) Non-alcoholic fatty liver disease and cardiovascular comorbidities: pathophysiological links, diagnosis, and therapeutic management. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics11040689","journal-title":"Diagnostics"},{"key":"2078_CR25","doi-asserted-by":"publisher","first-page":"682174","DOI":"10.1155\/2015\/682174","volume":"2015","author":"M Barone","year":"2015","unstructured":"Barone M, Viggiani MT, Amoruso A, Schiraldi S, Zito A, Devito F, Cortese F, Gesualdo M, Brunetti N, Di Leo A, Scicchitano P, Ciccone MM (2015) Endothelial dysfunction correlates with liver fibrosis in chronic HCV infection. Gastroenterol Res Pract 2015:682174\u2013682174. https:\/\/doi.org\/10.1155\/2015\/682174","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"2078_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.5009\/gnl18439","volume":"13","author":"DS Song","year":"2019","unstructured":"Song DS, Chang UI, Kang SG, Song SW, Yang JM (2019) Noninvasive serum fibrosis markers are associated with coronary artery calcification in patients with nonalcoholic fatty liver disease. Gut Liver 13(6):658\u2013668. https:\/\/doi.org\/10.5009\/gnl18439","journal-title":"Gut Liver"},{"issue":"8","key":"2078_CR27","doi-asserted-by":"publisher","first-page":"e104941","DOI":"10.1371\/journal.pone.0104941","volume":"9","author":"G Sesti","year":"2014","unstructured":"Sesti G, Sciacqua A, Fiorentino TV, Perticone M, Succurro E, Perticone F (2014) Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PLoS ONE 9(8):e104941\u2013e104941. https:\/\/doi.org\/10.1371\/journal.pone.0104941","journal-title":"PLoS ONE"},{"issue":"2","key":"2078_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/hep.31056","volume":"72","author":"G Carpino","year":"2020","unstructured":"Carpino G, Del Ben M, Pastori D, Carnevale R, Baratta F, Overi D, Francis H, Cardinale V, Onori P, Safarikia S, Cammisotto V, Alvaro D, Svegliati-Baroni G, Angelico F, Gaudio E, Violi F (2020) Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology 72(2):470\u2013485. https:\/\/doi.org\/10.1002\/hep.31056","journal-title":"Hepatology"},{"key":"2078_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005784","author":"D Pastori","year":"2017","unstructured":"Pastori D, Carnevale R, Nocella C, Novo M, Santulli M, Cammisotto V, Menichelli D, Pignatelli P, Violi F (2017) Gut-derived serum lipopolysaccharide is associated with enhanced risk of major adverse cardiovascular events in atrial fibrillation effect of adherence to mediterranean diet. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.005784","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2078_CR30","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1160\/TH16-11-0857","volume":"117","author":"C Nocella","year":"2017","unstructured":"Nocella C, Carnevale R, Bartimoccia S, Novo M, Cangemi R, Pastori D, Calvieri C, Pignatelli P, Violi F (2017) Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. Thromb Haemost 117(8):1558\u20131570. https:\/\/doi.org\/10.1160\/TH16-11-0857","journal-title":"Thromb Haemost"},{"issue":"5","key":"2078_CR31","doi-asserted-by":"publisher","first-page":"H1598","DOI":"10.1152\/ajpheart.01202.2008","volume":"296","author":"M Ni","year":"2009","unstructured":"Ni M, Wang Y, Zhang M, Zhang PF, Ding SF, Liu CX, Liu XL, Zhao YX, Zhang Y (2009) Atherosclerotic plaque disruption induced by stress and lipopolysaccharide in apolipoprotein E knockout mice. Am J Physiol Heart Circ Physiol 296(5):H1598-1606. https:\/\/doi.org\/10.1152\/ajpheart.01202.2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2078_CR32","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1038\/s41598-018-22076-4","volume":"8","author":"R Carnevale","year":"2018","unstructured":"Carnevale R, Nocella C, Petrozza V, Cammisotto V, Pacini L, Sorrentino V, Martinelli O, Irace L, Sciarretta S, Frati G, Pastori D, Violi F (2018) Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque. Sci Rep 8(1):3598. https:\/\/doi.org\/10.1038\/s41598-018-22076-4","journal-title":"Sci Rep"},{"issue":"9","key":"2078_CR33","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.2010.216077","volume":"59","author":"S McPherson","year":"2010","unstructured":"McPherson S, Stewart SF, Henderson E, Burt AD, Day CP (2010) Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59(9):1265\u20131269. https:\/\/doi.org\/10.1136\/gut.2010.216077","journal-title":"Gut"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02078-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-022-02078-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02078-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T13:06:21Z","timestamp":1675429581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-022-02078-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2078"],"URL":"https:\/\/doi.org\/10.1007\/s00392-022-02078-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}